Sangamo Therapeutics Inc (LTS:0R1D)
$ 1.9196 -0.0403 (-2.06%) Market Cap: 406.86 Mil Enterprise Value: 395.39 Mil PE Ratio: 0 PB Ratio: 10.37 GF Score: 34/100

Sangamo Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 10:20PM GMT
Release Date Price: $16.25
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

All right. Thanks again for tuning in to the JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst. And our next presenting company is Sangamo Therapeutics. With us to talk to a little -- talk to us a little bit about the company is CEO, Sandy Macrae. (Operator Instructions) With that, Sandy, thanks again for joining us this afternoon.

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Thank you, Eric. And I'm going to put the presentation up. And I'm going to ask you all to follow along, and I'll try and remember to say the numbers of the slide to help you do it.

So thank you for joining us for the Sangamo presentation. If there's 3 things I want you to take away from this presentation, it's how much Sangamo has achieved in 2020, our focus on delivery in '21, and the promise of this remarkable company. On the next slide, you can see our forward-looking statements, which, as always, I'd ask you to make sure to refer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot